References

1. Mohamed SY. Thalassemia Major: Transplantation or Transfusion and Chelation. Hematology/Oncology and Stem Cell Therapy. 2017;10(4):290-8.
2. De Sanctis V, Kattamis C, Canatan D, Soliman AT, Elsedfy H, Karimi M, et al. Beta-Thalassemia Distribution in the Old World: an Ancient Disease Seen from a Historical Standpoint. Mediterranean Journal of Hematology and Infectious Diseases. 2017;9(e2017018).
3. Chamberlain CX, Zagadailov E, Kistler K, Colby JA, Ruiz K, editors. Global Thalassemia Epidemiology: A Systematic Literature Review. 6th European Hematology Association (EHA) Annual Congress; 2021 June 9-17.
4. Chong CC, Redzuan AM, Sathar J, Makmor-Bakry M. Patient Perspective on Iron Chelation Therapy: Barriers and Facilitators of Medication Adherence. Journal Patient Experience. 2021;8:2374373521996958.
5. Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, et al. Consequences and Costs of Noncompliance with Iron Chelation Therapy in Patients with Transfusion-Dependent Thalassemia: a Literature Review. Transfusion. 2007;47(10):1919-29.
6. Reddy PS, Locke M, Badawy SM. A Systematic Review of Adherence to Iron Chelation Therapy among Children and Adolescents with Thalassemia. Annals of Medicine. 2022;54(1):326-42.
7. Arian M, Mirmohammadkhani M, Ghorbani R, Soleimani M. Health-Related Quality of Life (HRQoL) in Beta-Thalassemia Major (beta-TM) Patients assessed by 36-Item Short Form Health Survey (SF-36): a Meta-Analysis. Quality of Life Research. 2019;28(2):321-34.
8. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 Statement: an Updated Guideline for Reporting Systematic Reviews. BMJ. 2021;372:n71.
9. Raúl H, Álvarez-Pasquin MJ, Díaz C. Are Healthcare Workers’ Intentions to Vaccinate Related to Their Knowledge, Beliefs and Attitudes? a Systematic Review. BMC Public Health. 2013;13:154.
10. Wang J, Zhu CK, Yu JQ, Tan R, Yang PL. Hypoglycemia and Mortality in Sepsis Patients: A Systematic Review and Meta-analysis. Heart & Lung. 2021;50(6):933-40.
11. Al-Refaie FN, Wicken DG. Serum Non-transferrin-bound Iron in Beta-Thalassaemia Major Patients Treated with Desferrioxamine and L1. British Journal of Haematology. 1992(82):431-6.
12. Arboretti R, Tognoni G, Alberti D, Italian Colaborative Group on T. Pharmacosurveillance and Quality of Care of Thalassaemic Patients. European Journal of Clinical Pharmacology. 2001;56(12):915-22.
13. Kidson-Gerber GL, Francis S, Lindeman R. Management and Clinical Outcomes of Transfusion-Dependent Thalassaemia Major in an Australian Tertiary Referral Clinic. Medical Journal of Australia. 2008;188:72-5.
14. Lee W, Toh TH, Chai P, Soo T. Self-Reported Level of and Factors Influencing The Compliance to Desferrioxamine Therapy in Multitransfused Thalassaemias. Journal of Paediatrics and Child Health. 2011;47:535-40.
15. Haghpanah S, Nasirabadi S, Ghaffarpasand F, Karami R, Mahmoodi M, Parand S, et al. Quality of Life among Iranian Patients with Beta-Thalassemia Major Using the SF-36 Questionnaire. Sao Paulo Medical Journal. 2013;131(3):166-72.
16. Haghpanah S, Zarei T, Zahedi Z, Karimi M. Compliance and Satisfaction with Deferasirox (Exjade®) Compared with Deferoxamine in Patients with Transfusion-Dependent Beta-Thalassemia. Hematology. 2014;19(4):187-91.
17. Sobota A, Yamashita R, Xu Y, Trachtenberg F, Kohlbry P, Kleinert DA, et al. Quality of Life in Thalassemia: A Comparison of SF-36 Results from the Thalassemia Longitudinal Cohort to Reported Literature and the US Norms. American Journal of Hematology. 2011;86(1):92-5.
18. Bazi A, Sargazi-aval O, Safa A. Health-related Quality of Life and Associated Factors Among Thalassemia Major Patients, Southeast of Iran. Journal of Pediatric Hematology/Oncology. 2017;00:00.
19. Sobhani S, Rahmani F, Rahmani M, Askari M, Kompani F. Serum Ferritin Levels and Irregular Use of Iron Chelators Predict Liver Iron Load in Patients with Major Beta Thalassemia: a Cross-Sectional Study. Croatian Medical Journal. 2019;60(5):405-13.
20. Yassouf MY, Alquobaili F, Kabalan Y, Mukhalalaty Y. Compliance with Deferoxamine Therapy and Thyroid Dysfunction of Patients with beta-Thalassemia Major in Syria. HEMOGLOBIN (International Journal for Hemoglobin Research). 2019;43(3):218-21.
21. Sukhmani S, Shruti K, Priyanka D, Namita B, Praveen S. Adherence to Iron Chelation Therapy and Its Determinants. International Journal of Hematology-Oncology and Stem Cell Research. 2021;15(1).
22. Theppornpitak K, Trakarnsanga B, Lauhasurayotin S, Poparn H, Chiengthong K, Sosothikul D, et al. A Study to Assess and Improve Adherence to Iron Chelation Therapy in Transfusion-Dependent Thalassemia Patients. Hemoglobin. 2021;45(3):171-4.
23. Mahmoud RA, Khodeary A, Farhan MS. Detection of Endocrine Disorders in Young Children with Multi-Transfused Thalassemia Major. Italian Journal of Pediatrics. 2021;47(1):165.
24. Chai ASC, Draman N, Mohd Yusoff SS, Azman NF, Zulkifli MM, Yaacob NM, et al. Non-Compliance to Iron Chelation Therapy in Patients with Transfusion-Dependent Thalassaemia. Pediatric Hematology Oncology Journal. 2021;6(4):207-15.
25. Lam JCM, Lee SY, Koh PL, Fong SZ, Abdul-Kadir NI, Lim CY, et al. Clinical and Health-Related Quality of Life Outcomes of Transfusion-Dependent Thalassaemia Patients in Singapore. Blood Cells, Molecules and Diseases. 2021;88:102547.
26. Badur A, Ozbalci D, Alanoglu E. Evaluation of the Relationship between Sociodemographic Characteristics, Quality of Life, Depression, Drug Compliance and Biochemical Parameters in Patients with Thalassemia Major in Isparta. Annals of Medical Research. 2021;28(8).
27. Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R, et al. Prevention of Cardiac Disease by Subcutaneous Deferoxamine in Patients with Thalassemia Major. The New England Journal of Medicine. 1985;312(25):1600-3.
28. Richardson ME, Matthews RN, Alison JF, Menahem S, Mitvalsky J, Byrt E, et al. Prevention of Heart Disease by Subcutaneous Desferoxamine in Patients with Thalassaemia Major. Australian and New Zealand Journal of Medicine. 1993;23(6):656-61.
29. Mokhtar GM, Gadallah M, El Sherif NH, Ali HT. Morbidities and Mortality in Transfusion-Dependent Beta-Thalassemia Patients (Single-Center Experience). Pediatric Hematology and Oncology. 2013;30(2):93-103.
30. Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI. Efficacy and Safety of a Novel Combination of Two Oral Chelators Deferasirox/Deferiprone over Deferoxamine/Deferiprone in Severely Iron Overloaded Young Beta Thalassemia Major Patients. European Journal of Haematology. 2015;95(5):411-20.
31. Angelucci E, Barosi GC, C. Italian Society of Hematology Practice Guidelines for the Management of Iron Overload in Thalassaemia Major and Related Disorders. Haematologica. 2008:93:5.
32. Mohd Ibrahim H, Afifah H, Elizabeth G. Clinical Practical Guidelines Management of Transfusion Dependent Thalassaemia. Malaysia. 2009.
33. Walker JM. Thalassaemia Major and the Heart: a Toxic Cardiomyopathy Tamed? Heart. 2013:827-34.
34. Al-Kloub MI, MA AB, Al Khawaldeh OA, Al Tawarah YM, Froelicher ES. Predictors of Non-Adherence to Follow-Up Visits and Deferasirox Chelation Therapy among Jordanian Adolescents with Thalassemia Major. Pediatric Hematology and Oncology. 2014;31(7):624-37.
35. Richardson ME, Matthews RN, Alison JF, Menahem S. Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaernia major.